CDT Equity (NASDAQ:CDT – Get Free Report) and Mannatech (NASDAQ:MTEX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Valuation & Earnings
This table compares CDT Equity and Mannatech”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CDT Equity | N/A | N/A | -$39.22 million | ($66,338.55) | 0.00 |
| Mannatech | $108.04 million | 0.09 | -$15.21 million | ($8.00) | -0.61 |
Profitability
This table compares CDT Equity and Mannatech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CDT Equity | N/A | -4,263.33% | -529.91% |
| Mannatech | -14.08% | -398.35% | -45.63% |
Analyst Recommendations
This is a breakdown of current recommendations for CDT Equity and Mannatech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CDT Equity | 1 | 0 | 0 | 0 | 1.00 |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
CDT Equity has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Institutional & Insider Ownership
3.3% of CDT Equity shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Mannatech beats CDT Equity on 7 of the 10 factors compared between the two stocks.
About CDT Equity
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.
